已发表论文

中国2型糖尿病住院患者开始使用德谷胰岛素——单中心经验

 

Authors Qiang W , Li M , Song S, Dong R , Zhang T , Kou X, Wu Y, Wang Z, Liu J , Liu J, Wang Y, Wu X, Shi B, Guo H

Received 6 May 2024

Accepted for publication 16 August 2024

Published 21 September 2024 Volume 2024:17 Pages 3535—3546

DOI https://doi.org/10.2147/DMSO.S468070

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Antonio Brunetti

Wei Qiang,1,* Mengyi Li,1,2,* Sucai Song,1,3 Ruiqing Dong,1 Tongxin Zhang,1 Xuna Kou,1 Yuan Wu,1 Zhaoxu Wang,1,4 Jiayue Liu,1 Juan Liu,1 Yi Wang,1 Xiaoyan Wu,1 Bingyin Shi,1 Hui Guo1 

1Department of Endocrinology and Metabolism, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of Endocrinology, Xi’an People’s Hospital, Xi’an, Shaanxi, 710100, People’s Republic of China; 3Department of Endocrinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 4Department of Endocrinology, Luohe Central Hospital, Luohe, Henan, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hui Guo, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University, 277 Yanta West Street, Xi’an, People’s Republic of China, Tel +86-13709292996, Fax +86-029-85323974, Email 13709292996@139.com

Introduction: The long-acting insulin analogue insulin degludec (IDeg) is increasingly recommended for type two diabetes (T2DM), yet clinical experience in China remains limited. This retrospective study aimed to delineate the initiation strategy for IDeg in Chinese hospitalized patients with T2DM.
Methods: We retrospectively analyzed 217 Chinese hospitalized patients with T2DM who initiated IDeg from December 2018 to June 2020, calculating the initial dose and examining correlations between clinical characteristics and glucose profiles.
Results: The initial IDeg doses ranged from 0.15 to 0.18 IU/kg·d, showing no association with clinical characteristics. During titration, mean blood glucose levels (MEAN) correlated positively with diabetes duration, age, and Glycosylated Hemoglobin (HbA1c), and negatively with body mass index (BMI), triglycerides (TG), and low-density lipoprotein (LDL). The coefficient of variation (CV) in glucose levels correlated positively with HbA1c and negatively with BMI and TG. The mean amplitude of glycemic excursions (MAGE) mirrored these trends, with additional negative correlations to estimated glomerular filtration rate (eGFR) and serum albumin (ALB). Notably, glycemic variability parameters did not correlate with the presence of diabetic ketoacidosis (DKA) at admission. Hypoglycemia was observed in 21 patients, with differences in MEAN and CV during titration being the only significant findings.
Conclusion: The initial IDeg dosing was inadequate and not tailored to clinical features, and there were weak correlations between diabetes duration, age, BMI, eGFR, LDL, and ALB levels and glucose profile post-initiation.

Keywords: T2DM, insulin degludec, glucose variability, insulin initiation